Viewing data from:

CYCLOPHOSPHAMIDE

NDA

CYCLOPHOSPHAMIDE | N203856 | HIKMA PHARMACEUTICALS USA INC

2 strengths0 unique patents0 unique exclusivities

PTAB Proceedings

No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board

Patent Reexaminations

No ex parte or inter partes reexamination proceedings found at USPTO

Hatch-Waxman Litigation

No ANDA patent litigation cases (NOS 835) matched from PACER

Citizen Petitions

No FDA citizen petitions matched from Regulations.gov

Clinical Trials

No clinical trials found on ClinicalTrials.gov for this drug

Medicare Part B Spending

CMS physician-administered drug spending for Cyclophosphamide (J9070) (2023)

Total Spending

$19.8M

Total Claims

88,921

Beneficiaries

23,197

ASP Price

$19.70

Spending Trend

$524K(2023)→$19.8M(2023)→$1.2M(2023)

YoY Change:-20.9%

5yr CAGR:-11.9%

HCPCS: J9070 — Cyclophosphamide, 100 mg

Source: CMS Medicare Part B Spending by Drug (2023). Shows physician-administered drug costs.

API Supply Chain14 active DMFs11 inactive

12 active API suppliers hold Drug Master Files for this ingredient.

BAXTER ONCOLOGY GMBHCYCLOPHOSPHAMIDE INJECTION VIALS

DMF 37161980

ZHEJIANG HISUN PHARMACEUTICAL CO LTDCYCLOPHOSPHAMIDE USP

DMF 151782000

HETERO LABS LTDCYCLOPHOSPHAMIDE MONOHYDRATE, USP

DMF 267532012

EMCURE PHARMACEUTICALS LTDCYCLOPHOSPHAMIDE USP

DMF 298392015

MSN LABORATORIES PRIVATE LTDCYCLOPHOSPHAMIDE MONOHYDRATE USP

DMF 310882016

AMPAC FINE CHEMICALS LLCCYCLOPHOSPHAMIDE MONOHYDRATE

DMF 324922018

SUNNY PHARMTECH INCCYCLOPHOSPHAMIDE USP

DMF 332912019

SHILPA PHARMA LIFESCIENCES LTDCYCLOPHOSPHAMIDE USP

DMF 340662019

AARTI PHARMALABS LTDCYCLOPHOSPHAMIDE STERILE USP

DMF 353132021

NAVINTA LLCCYCLOPHOSPHAMIDE USP (STERILE)

DMF 359752021

APICORE LLCCYCLOPHOSPHAMIDE USP (STERILE BULK)

DMF 360892021

AARTI PHARMALABS LTDCYCLOPHOSPHAMIDE

DMF 370862022

ANHUI POLY PHARM CO LTDCYCLOPHOSPHAMIDE USP

DMF 371542022

NAVINTA LLCCYCLOPHOSPHAMIDE USP

DMF 382322023

FERMION OYInactiveCYCLOPHOSPHAMIDE ORAL GRADE

DMF 32721978

ASTA WERKE AKTIENGESELLSCHAFTInactiveCYCLOPHOSPHAMIDE TABLETS

DMF 47241982

ORION CORPInactiveCYCLOPHOSPHAMIDE 50 MG TABLETS

DMF 52981984

BEN VENUE LABORATORIES INCInactiveCYCLOPHOSPHAMIDE LYOPHILIZED FOR INJ(5 DOSAGE FORMS)BEDFORD,OHIO FAC

DMF 55411984

PHARM ECO LABORATORIES INCInactiveCYCLOPHOSPHAMIDE MONOHYDRATE

DMF 63981985

ORION CORP FARMOS CHEMICAL PLANTInactiveCYCLOPHOSPHAMIDE 50 MG. TABL.

DMF 73411988

LIANYUNGANG PHARMACEUTICAL FACTORYInactiveCYCLOPHOSPHAMIDE USP,NON-STERILE BULK DRUG

DMF 130501998

DEGUSSA HULS AGInactiveCYCLOPHOSPHAMIDE

DMF 148302000

OLAINFARM JOINT STOCK COInactiveCYCLOPHOSPHAMIDE

DMF 170652003

EMCURE PHARMACEUTICALS LTDInactiveCYCLOPHOSPHAMIDE USP

DMF 227942009

SUNNY PHARMTECH INCInactiveCYCLOPHOSPHAMIDE

DMF 261372012

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Approval Letters

2 letters from Drugs@FDA

Date	Submission	Document
Sep 27, 2019	SUPPL -3	View Letter (PDF)
Sep 19, 2013	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (2)

Sort:

#001 — 25MG

RLDAB

0 patents0 exclusivities▴

CAPSULE;ORAL | Approved: Sep 16, 2013

No patent or exclusivity listings for this strength.

#002 — 50MG

RLDAB

0 patents0 exclusivities▾

CAPSULE;ORAL | Approved: Sep 16, 2013